<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251132</url>
  </required_header>
  <id_info>
    <org_study_id>1182.5</org_study_id>
    <nct_id>NCT02251132</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Parallel Group, Multiple-dose Investigation of the Pharmacokinetics of Tipranavir Soft Elastic Capsules SEDDS and Ritonavir Soft Gel Capsules and Their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the tipranavir-ritonavir steady-state
      dose-exposure relationships when administered on a b.i.d. dosing regimen; to determine the
      effects of tipranavir (TPV) and ritonavir (RTV) on cytochrome P-450 (CYP3A4) activity; to
      establish the dependency of the TPV M1 metabolite on RTV co-administration. Additionally, the
      short-term safety and tolerance of this drug combination will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough plasma concentration at steady state (Cmin,ss)</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax,ss)</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (tmax)</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from 0 to 12 hours (AUC0-12)</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (Cl/F)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half life (t1/2)</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of erythromycin metabolized per hour</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Erythromycin breath test (ERMBT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 32 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/RTV Low 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV Low 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV Low 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV Medium 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV Medium 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV High 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV High 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPV/RTV High 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV low 1</intervention_name>
    <arm_group_label>TPV/RTV Low 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV low 2</intervention_name>
    <arm_group_label>TPV/RTV Low 2</arm_group_label>
    <arm_group_label>TPV/RTV Low 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV medium</intervention_name>
    <arm_group_label>TPV/RTV Medium 1</arm_group_label>
    <arm_group_label>TPV/RTV Medium 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV high 1</intervention_name>
    <arm_group_label>TPV/RTV High 1</arm_group_label>
    <arm_group_label>TPV/RTV High 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPV high 2</intervention_name>
    <arm_group_label>TPV/RTV High 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV low</intervention_name>
    <arm_group_label>TPV/RTV Low 2</arm_group_label>
    <arm_group_label>TPV/RTV Medium 1</arm_group_label>
    <arm_group_label>TPV/RTV High 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir high</intervention_name>
    <arm_group_label>TPV/RTV Low 1</arm_group_label>
    <arm_group_label>TPV/RTV Low 3</arm_group_label>
    <arm_group_label>TPV/RTV Medium 2</arm_group_label>
    <arm_group_label>TPV/RTV High 2</arm_group_label>
    <arm_group_label>TPV/RTV High 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabelled erythromycin</intervention_name>
    <arm_group_label>TPV/RTV Low 1</arm_group_label>
    <arm_group_label>TPV/RTV Low 2</arm_group_label>
    <arm_group_label>TPV/RTV Low 3</arm_group_label>
    <arm_group_label>TPV/RTV Medium 1</arm_group_label>
    <arm_group_label>TPV/RTV Medium 2</arm_group_label>
    <arm_group_label>TPV/RTV High 1</arm_group_label>
    <arm_group_label>TPV/RTV High 2</arm_group_label>
    <arm_group_label>TPV/RTV High 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 75 years of age inclusive

          -  Female subjects of child-bearing potential are required to use a barrier contraceptive
             method for at least 3 months prior to administration of study medication, during study
             medication administration and for 30 days after the end of the study

          -  Ability to swallow numerous large capsules without difficulty

          -  A body mass index (BMI) between 19 and 29 kg/m2

          -  Signed informed consent prior to trial participation

          -  Reasonable probability for completion of the study

          -  Acceptable screening laboratory values that indicate adequate baseline organ function
             are required at the time of screening. Laboratory values are considered to be
             acceptable if severity is no higher than Grade 1 based on the AIDS Clinical Trials
             Group (ACTG) Grading Scale. All laboratory values &gt; Grade 1 are subject to approval by
             the BIPI clinical monitor

          -  Acceptable medical history, physical examination, electrocardiogram, and chest X-ray
             are required prior to entering the treatment phase of the study

          -  Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from
             alcohol for the duration of the study

          -  Willingness to abstain from ingesting grapefruit or grapefruit juice for the duration
             of the study

          -  Urine drug screen negative for drugs of abuse

          -  Negative HIV serology

          -  Negative for Hepatitis B surface antigen and Hepatitis C antibody

        Exclusion Criteria:

          -  Female subjects who:

               -  have a positive serum pregnancy test at Visits 1 or 2 OR

               -  are breastfeeding

          -  Receipt of any other investigational medicine for 30 days prior to Day 0

          -  Receipt of any known enzyme altering drug for 30 days prior to Day 0, grapefruit and
             grapefruit juice within 15 days prior to Day 0 and antibiotics within 10 days prior to
             Day 0

          -  Excessive cigarette smoking, defined as greater than 10 cigarettes per day

          -  Blood or plasma donation within 30 days prior to Day 0

          -  Subjects with a seated systolic blood pressure either &lt; 100 mg Hg or &gt; 150 mm Hg;
             resting heart rate either &lt; 50 beats/min or &gt; 90 beats/min

          -  Subjects with a history of any illness or allergy that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk in
             administering tipranavir or ritonavir to the subject

          -  Subjects who have had an acute illness within 2 weeks prior to Day 0

          -  Subjects who are currently taking any over-the-counter drug within 7 days prior to Day
             0, or who are currently taking any prescription drug that, in the opinion of the
             investigator in consultation with the BIPI medical monitor and pharmacokineticist,
             might interfere with either the absorption, distribution or metabolism of the test
             substances

          -  Hypersensitivity to tipranavir, ritonavir or sulfonamide containing drugs

          -  Evidence of active substance abuse that, in the investigator's opinion, could affect
             study adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

